- Home
- SEGG vs GDTC Comparison
SEGG vs GDTC Comparison
Compare SEGG & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEGG | GDTC |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | Singapore |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 12.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEGG | GDTC |
|---|---|---|
| Price | $1.26 | $0.98 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 5.2K |
| Earning Date | 05-20-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.73 |
| 52 Week High | $7.61 | $3.68 |
Technical Indicators
Market Signals| Indicator | SEGG | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 44.84 |
| Support Level | $1.06 | $0.88 |
| Resistance Level | $1.56 | $1.06 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 66.38 | 58.33 |
Price Performance
Historical ComparisonAbout SEGG Lottery.com Inc.
Sports Entertainment Gaming Global Corp is a sports, entertainment and gaming group operating digital assets such as Sports.com and Lottery.com. It is focused on immersive fan engagement, ethical gaming and AI-driven live experiences.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.